In:
Cancer, Wiley, Vol. 121, No. 23 ( 2015-12), p. 4205-4211
Abstract:
Different preparations of asparaginase are used in the treatment of pediatric acute lymphoblastic leukemia, and the optimal use of this agent has yet to be elucidated. The authors observe differences in the incidence of toxicity with various asparaginase preparations and demonstrate that antiasparaginase antibodies do not affect event‐free survival.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v121.23
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1